The highlight of the first day were a number of novel modes of drug action for treatment of neurodegenerative diseases. Targeted Protein Degradation was attempted by PROTACs and antibodies against target protein aggregates. Antibody sequence optimization was proposed for best brain and cell penetration, and intracellular activity. Transgenic antibody production inside the disease hosts (gene therapy) was also suggested to eradicate disease-inducing protein aggregates. Strategies suppressing disease protein aggregation or monomer stabilization were shown. Furthermore, multiple attempts to stabilize calcium homeostasis in neurodegenerative diseases to prevent neuronal damage and apoptosis were presented. Novel and more comprehensive mouse models were presented to better evaluate drug effects in early mild to moderate, rather than late stage disease; and taking tau-aggregate toxicity into AD models.
Type: Conference
Status: Active
Venue: Munich, Germany
Date: 2026-05-04 to 2026-05-05
Deadline: 2026-04-29
46--Health